MRNA:NSD-Moderna, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 169.50

Change

+12.72 (+8.11)%

Market Cap

USD 61.85B

Volume

0.01B

Average Target Price

USD 155.83 (-8.06%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., and Recipharm for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-0.40 (-0.18%)

USD56.98B 21.40 15.53
REGN Regeneron Pharmaceuticals, Inc

+2.06 (+0.41%)

USD54.04B 16.53 12.83
ALXN Alexion Pharmaceuticals, Inc

+1.90 (+1.14%)

USD36.79B 61.23 35.79
BNTX BioNTech SE

+5.62 (+3.60%)

USD36.10B -99,999.99 N/A
BGNE BeiGene, Ltd

+9.25 (+3.16%)

USD27.46B N/A N/A
SGEN Seagen Inc

+2.73 (+1.89%)

USD26.25B 42.96 35.78
RPRX Royalty Pharma plc

+1.34 (+3.23%)

USD25.16B 22.60 15.19
GMAB Genmab A/S

+0.82 (+2.29%)

USD23.17B 26.59 3.31
CVAC CureVac N.V

+2.16 (+1.95%)

USD21.12B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing MRNA

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

+2.55 (+1.39%)

USD0.50B
MXDU Nationwide Maximum Divers.. 0.00 % 0.34 %

+0.31 (+0.78%)

USD0.11B
EL41:XETRA Deka MSCI USA MC UCITS ET.. 0.00 % 0.30 %

+0.33 (+1.42%)

USD0.03B
XRSM:F Xtrackers (IE) Plc - Xtra.. 0.00 % 0.35 %

+0.19 (+0.66%)

USD0.11B
XRMU:LSE Xtrackers (IE) Plc - Xtra.. 0.00 % 0.35 %

+0.34 (+0.97%)

USD0.12B
FEXU:LSE First Trust US Large Cap .. 0.00 % 0.75 %

+0.55 (+0.85%)

USD0.09B
FEXD:LSE First Trust US Large Cap .. 0.00 % 0.75 %

+38.00 (+0.87%)

USD0.09B
FEX:LSE First Trust US Large Cap .. 0.00 % 0.75 %

+40.50 (+0.87%)

USD0.08B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.16 (+2.28%)

USD0.03B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.11 (+2.26%)

USD0.34B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.15 (+2.27%)

USD0.34B
LS:CA Middlefield Healthcare & .. 0.00 % 0.85 %

+0.01 (+0.09%)

USD0.08B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

+0.33 (+0.78%)

USD0.04B
BTEC Principal Healthcare Inno.. 0.00 % 0.42 %

+1.67 (+2.94%)

USD0.16B
RBUS Nationwide Risk-Based U.S.. 0.00 % 0.30 %

+0.20 (+0.54%)

USD0.11B
AIEQ AI Powered Equity ETF 0.00 % 0.80 %

+0.90 (+2.35%)

USD0.16B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+3.23 (+3.80%)

USD0.20B
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.35 %

+1.12 (+1.46%)

USD0.51B
VXF Vanguard Extended Market .. 0.00 % 0.06 %

+3.50 (+1.96%)

USD106.09B
TUSA First Trust Total US Mark.. 0.00 % 0.70 %

+0.23 (+0.48%)

USD0.02B
MWD:CA Mackenzie Maximum Diversi.. 0.00 % 0.50 %

-0.04 (-0.14%)

USD0.46B
MUS:CA Mackenzie Maximum Diversi.. 0.00 % 0.45 %

-0.07 (-0.20%)

USD0.17B
JKH iShares Morningstar Mid-C.. 0.00 % 0.06 %

N/A

USD1.59B
IWP iShares Russell Mid-Cap G.. 0.00 % 0.24 %

+1.35 (+1.27%)

USD15.18B
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.46 %

+2.99 (+1.97%)

USD10.74B
FXH First Trust Health Care A.. 0.00 % 0.61 %

+1.57 (+1.38%)

USD1.38B
FTC First Trust Large Cap Gro.. 0.00 % 0.60 %

+1.22 (+1.19%)

USD1.04B
FLAG FLAG-Forensic Accounting .. 0.00 % 1.44 %

N/A

USD4.83M
FHH:CA FT AlphaDEX U.S. Health C.. 0.00 % 0.70 %

+0.23 (+0.59%)

USD0.02B
FEX First Trust Large Cap Cor.. 0.00 % 0.59 %

+1.02 (+1.24%)

USD1.10B
FAD First Trust Multi Cap Gro.. 0.00 % 0.63 %

+2.01 (+1.83%)

USD0.21B
XRSM:XETRA Xtrackers (IE) Plc - Xtra.. 0.00 % 0.35 %

+0.33 (+1.15%)

USD0.12B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 62.25% 91% A- 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.25% 91% A- 92% A-
Trailing 12 Months  
Capital Gain 231.05% 91% A- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 231.05% 91% A- 88% B+
Trailing 5 Years  
Capital Gain N/A 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A 100% A+ 100% A+
Average Annual (5 Year Horizon)  
Capital Gain 852.58% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 852.58% 99% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 1,021.95% 2% F 2% F
Risk Adjusted Return 83.43% 96% A 89% B+
Market Capitalization 61.85B 100% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 25.32 6% F 5% F
Price / Cash Flow Ratio 30.51 5% F 15% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -39.99% 68% D+ 27% F
Return on Invested Capital -40.99% 60% D- 20% F
Return on Assets -10.69% 84% B 28% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.45 71% C- 62% D-
Short Percent 4.43% 65% D 42% F
Beta 1.38 50% F 36% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector